Home › NCT05504681

Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. All adult (18+) patients with central nervous system (CNS) tumors, both primary brain malignancies and brain metastases, treated with radiotherapy (partial brain, stereotactic radiosurgery, stereotactic fractionated radiotherapy, or whole-brain radiotherapy), surgery, and/or antineoplastic therapy and followed thereafter at Miami Cancer Institute (MCI)
2. Life expectancy ≥ 6 months
3. Willingness to participate in ongoing registration study

Exclusion Criteria:

1. Patients receiving radiotherapy to the brain for functional disease (arteriovenous malformations, trigeminal neuralgia, essential tremors, etc.)
2. Pediatric patients (\<18 years old), pregnant women, and prisoners.

About the study

This is prospective observational registry study that will assess 1) if the neurocognitive function app (Brainlab Cognition) can be used in a widespread neuro-oncology clinic setting and 2) if patient reported quality of life parameters can be obtained electronically and integrated into clinic.

What is being tested

• Observational study (other)

Sponsor: Baptist Health South Florida · Participants: 200 · Started: Nov 30, 2021

Contact the study team

• Rupesh R Kotecha · Phone: 17865962000

Official record on ClinicalTrials.gov — NCT05504681

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.